The Biological Activity of Cediranib (AZD2171) in Gastro-Intestinal Stromal Tumours(GIST).

Phase 2 Completed 35 enrolled AstraZeneca

Non-randomizedSingle-groupOpen-labelTreatment

Summary

To determine the anti-tumour activity and biological effects of cediranib (AZD2171) at a dose of 45mg, primarily in Gastrointestinal Stromal Tumour (GIST) patients who are resistant to imatinib mesylate (current standard therapy) and also in patients with metastatic Soft Tissue Sarcoma (STS) resistant to standard therapy.

Timeline

Start: 2006-09
Primary completion: 2008-06
Completion: 2009-12

Outcome

Missed primary endpoint

paper but did not reduce average SUVmax. PMID 24714778 ↗

Publications

Judson I, Scurr M, Gardner K, Barquin E, Marotti M, Collins B, Young H, Jurgensmeier JM, Leahy M. Phase II study of cediranib in patients with advanced gastrointestinal stromal tumors or soft-tissue sarcoma. Clin Cancer Res. 2014 Jul 1;20(13):3603-12. doi: 10.1158/1078-0432.CCR-13-1881. Epub 2014 Apr 8.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Cediranib	Small molecule	45 mg	Oral